World-first Trial for Tendon Repair Using Tendon Stem Cells Published in the Prestigious American Journal of Sports Medicine

World-first Trial for Tendon Repair Using Tendon Stem Cells Published in the Prestigious American Journal of Sports Medicine

SOURCE  Orthocell Limited

PERTH, Australia, Oct. 2, 2013 /PRNewswire/ — Regenerative medicine  company, Orthocell Limited (Orthocell), today announced the results of its  unprecedented and successful clinical trial for the treatment of tendon injuries  using its patented stem cell technology. Tendon injuries are one of the most  common causes of occupational and sporting disability and current clinical  treatments are only moderately effective.

Orthocell’s new technique is known as Autologous Tenocyte Implantation  (Ortho-ATIT) and involves biopsy of the patient’s own healthy tendon, isolation  and cultivation of tendon stem cells from the biopsy in a special laboratory and  then injection of these cells back to the injured tendon. The process takes  about 20-minutes and is less invasive than surgery.

The company has received international profiling and recognition in the  prestigious American Journal of Sports Medicine (AJSM), with a peer reviewed  publication of the world first study on Ortho-ATIT stem cell technology for  regeneration of damaged human tendon.

The AJSM, which is ranked as the world’s number one journal for orthopaedics  and sports medicine, published outcomes of the clinical trial last week. The  data demonstrates that Orthocell’s novel technology for repairing tendons was a  safe and effective procedure that enables a reduction in pain and repairs tendon  in severe chronic resistant tendon injury, like tennis elbow. The patients  treated in the study, had failed at least one previous therapy including  physiotherapy and corticosteroid injection. Patients achieved significant  improvement in function and structural integrity of the tendon after the  Ortho-ATIT tendon stem cell injection.

Orthocell Managing Director Paul Anderson said  the clinical study indicates great potential for the Ortho-ATIT stem cell tendon  repair.

“The AJSM paper is a benchmark study that validates the repair of tendon  using tendon derived stem cells. We are now focussing our efforts on offering  this world class treatment more widely to patients throughout Australasia, and  we are also investigating new potential markets overseas,” said Mr Anderson.

The technique was the result of more than 10 years development by Professor Ming Hao Zheng’s group at the Centre for  Translational Orthopaedic Research at the University of Western  Australia, one of the top one hundred universities in the World.

“This is a very exciting body of work, which is indicated for a large patient  population. There are currently limited treatment options for people suffering  from tendon injury and related disorders, as there are no targeted drug  therapies and surgery often delivers unsatisfactory results. This published  study of Ortho-ATIT strongly suggested that substitution of tendon stem cells  enables regeneration of tendon,” said Professor Zheng.

Amanda Redwood, a 45-year-old mother of two  who participated in the trial, said Orthocell’s treatment relieved her of severe  elbow pain within 6 months.

“I experienced debilitating symptoms of tennis elbow for more than 16-months  before I had the procedure. Within 6 weeks of the injection the pain started to  subside, and within 6 months it was gone,” said Ms Redwood.

“As a result of this condition I was unable to play tennis and netball with  my 2 girls and I could barely lift anything without severe pain, not even a  glass of water. It made even the most menial of tasks difficult, so I am  delighted that I’ve been able to make a full recovery so quickly, without  surgery.”

Ortho-ATIT has been approved by the Therapeutics Goods Administration (TGA)  in Australia. The technology is currently  available to patients in Australasia who have failed conservative treatment.  More information about treatment options can be obtained by contacting Orthocell  directly or visiting the company website.

About Orthocell

Orthocell Limited (Orthocell) is a Regenerative Medicine company seeking to  address unmet clinical needs within the global soft tissue repair market. Its  core focus is biological therapies for tendon and ligament tissue repair and  regeneration. Orthocell’s technology will deliver the first truly effective  regenerative solution for Tendonopathy related injuries.